Granata Antonio, Sessa Adalberto, Righetti Marco, Cordaro Sarah, Leone Giorgio, Figura Mariapia, Fatuzzo Pasquale, Rapisarda Francesco, Di Maria Emilio, Ciotti Paola, Mandich Paola, Nardo Alfio, Ferrone Marina, Gallone Salvatore, Liuzzo Gabriele
Department of Nephrology and Dialysis, Garibaldi - S. Luigi - Ascoli Tomaselli Hospital, Catania, Italy.
J Nephrol. 2004 Mar-Apr;17(2):306-10.
Von Hippel-Lindau (VHL) disease is an autosomal dominant syndrome characterized by germline mutations in the VHL tumor suppressor gene located at chromosome 3p25-26 and pleomorphic clinical picture. The major clinical manifestations include retinal angiomas, central nervous system hemangioblastomas, pheopleochromocytoma, pancreatic cysts, epididymal cystoadenomas and renal lesions. Recently, we observed a 58-year-old male patient with macrohematuria and a history of nephrectomy due to renal cell carcinoma (RCC). The patient showed retinal angiomatosis, cerebellar hemangioblastomas, multiple pancreatic cysts, right kidney with polycystic features plus two RCC. The patient's offspring, two females and one male, showed VHL lesions, such as retinal angiomatosis, cerebellar hemangioblastomas and polycystic kidney disease (PKD). The affected family members were screened for mutations in the VHL gene. Data suggested the presence of a deletion encompassing exon 1 of the VHL gene. Early diagnosis of VHL disease in patients and their relatives is important for clinical and geneticreasons. VHL disease patients have an increased incidence of malignant carcinomas and the syndrome can mimic the presentation of other cystic kidney diseases. Early diagnosis and molecular genetic testing of family members is essential to improve the clinical management of patients and to allow an accurate risk assessment in asymptomatic individuals. In conclusion, nephrologists and urologists must carefully evaluate patients with PKD and RCC to confirm or exclude VHL disease, and physicians must play a crucial role in the clinical process of therapeutical decisions and choices for VHL patients.
冯·希佩尔-林道(VHL)病是一种常染色体显性综合征,其特征为位于3号染色体p25 - 26区域的VHL肿瘤抑制基因发生种系突变,临床表现多样。主要临床表现包括视网膜血管瘤、中枢神经系统血管母细胞瘤、嗜铬细胞瘤、胰腺囊肿、附睾囊腺瘤和肾脏病变。最近,我们观察到一名58岁男性患者,有肉眼血尿病史,因肾细胞癌(RCC)接受过肾切除术。该患者表现出视网膜血管瘤病、小脑血管母细胞瘤、多个胰腺囊肿、具有多囊特征的右肾以及两个肾细胞癌。患者的后代,两女一男,表现出VHL病变,如视网膜血管瘤病、小脑血管母细胞瘤和多囊肾病(PKD)。对受影响的家庭成员进行了VHL基因突变筛查。数据表明存在一个包含VHL基因第1外显子的缺失。出于临床和遗传原因,对患者及其亲属进行VHL病的早期诊断很重要。VHL病患者患恶性肿瘤的发生率增加,该综合征可模仿其他囊性肾病的表现。对家庭成员进行早期诊断和分子遗传学检测对于改善患者的临床管理以及对无症状个体进行准确的风险评估至关重要。总之,肾病学家和泌尿科医生必须仔细评估患有多囊肾病和肾细胞癌的患者,以确认或排除VHL病,并且医生在VHL病患者的治疗决策和选择的临床过程中必须发挥关键作用。